Psoriatic Arthritis (PsA)

Psoriatic arthritis is a chronic inflammatory arthritis associated with psoriasis. It can involve peripheral joints, entheses (tendon insertion sites), the spine, and digits, leading to pain, swelling, and structural damage. Early treatment prevents disability and improves skin outcomes.

Clinical Patterns

• Peripheral arthritis: oligoarticular or polyarticular
• Axial disease: sacroiliitis, spondylitis
• Enthesitis: Achilles, plantar fascia, costochondral junctions
• Dactylitis (“sausage digits”): diffuse finger/toe swelling
• Nail disease: pitting, onycholysis, hyperkeratosis

Risk Factors

• Family history of psoriasis/PsA
• Early-onset severe psoriasis, nail involvement
• Obesity, smoking, infections
• Trauma (Koebner phenomenon) at entheses

Symptoms

• Joint stiffness, particularly in the morning
• Swelling and redness around joints or entheses
• Lower back or buttock pain (axial involvement)
• Fatigue, eye inflammation (uveitis), inflammatory bowel disease symptoms
• Psoriasis flares often parallel joint flares

Diagnosis

• CASPAR criteria combine clinical psoriasis signs with imaging/lab evidence
• Labs: ESR/CRP may be elevated; RF/CCP usually negative (helps distinguish from RA)
• Imaging: X-ray shows pencil-in-cup deformities, periostitis; ultrasound/MRI detect synovitis, enthesitis
• Screen for comorbidities: metabolic syndrome, cardiovascular risk, depression

Treatment & Management

Lifestyle & Self-Care

• Anti-inflammatory diet emphasizing omega-3s, whole grains, lean protein
• Regular low-impact exercise, stretching, strength training
• Smoking cessation, weight management
• Manage stress with mindfulness or therapy; psoriasis flares can trigger joint flares

Medications

• NSAIDs for mild cases
• Conventional DMARDs: methotrexate, sulfasalazine, leflunomide
• Biologics: TNF inhibitors, IL-17 inhibitors (secukinumab), IL-12/23 (ustekinumab), IL-23 inhibitors (guselkumab), abatacept
• Targeted small molecules: JAK inhibitors (upadacitinib), PDE4 inhibitors (apremilast)
• Topicals/phototherapy for cutaneous psoriasis
• Vaccinations prior to biologics to reduce infection risk

Procedures

• Joint injections (corticosteroid) for localized flares
• Orthotics or splints for enthesitis and dactylitis
• Joint replacement in advanced damage

Living with PsA

• Keep a joint and skin symptom diary, including triggers or infections
• Coordinate care between rheumatologist and dermatologist
• Protect joints during daily activities; consider adaptive tools
• Address mental health—PsA carries a high burden of depression and anxiety

Complications

• Joint erosions and deformities
• Eye inflammation (uveitis), inflammatory bowel disease
• Increased cardiovascular risk
• Reduced quality of life from chronic pain and visible skin lesions

Research & Future Directions

Studies explore biomarkers predicting biologic response, precision targeting of IL-23/Th17 pathways, and patient-specific digital twins for treat-to-target strategies.

Experimental & Emerging Treatments

• Dual Pathway Biologics: Agents blocking multiple cytokines simultaneously (e.g., IL-17 + TNF) are under investigation for refractory PsA.
• TYK2 Inhibitors: Oral agents (deucravacitinib) show promise for both skin and joint disease.
• CAR-Treg Therapy: Early research aims to restore immune tolerance at entheses without broad immunosuppression.
• Microbiome Interventions: Fecal microbiota transplant and targeted probiotics are being studied for their impact on systemic inflammation.

Track PsA with Diagnoza.care

Sync Skin & Joint Care – Log flares, pain scores, enthesitis sites, skin severity, medications, and lab results, schedule rheumatology and dermatology visits, capture side effects, and let the AI companion highlight patterns tied to stress, infections, or lifestyle.

---

Medical Disclaimer: Informational only. Work with your rheumatologist and dermatologist to confirm diagnosis and tailor biologic or small-molecule therapy. Sources: American College of Rheumatology, National Psoriasis Foundation, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)